Research

Hormonal

ETC-1002 (ESP55016) reduces circulating proatherogenic lipoproteins, hepatic lipids, and body weight in hyperlipidemic hamsters and improves glycemic control in diet-induced obese mice through dual inhibition of ATP-citrate lyase and activation of AMP-activated protein kinase.

ETC-1002 is an investigational small molecule designed to treat dyslipidemia and metabolic syndrome. In animal models, it lowered LDL cholesterol, reduced body weight, and improved blood sugar control by simultaneously activating AMPK (energy sensor) and inhibiting ATP-citrate lyase (lipid synthesis enzyme). It is not currently available for general use.

ModerateSupportsMEDIUM confidence
Consistent with these mechanisms, ETC-1002 treatment reduced circulating proatherogenic lipoproteins, hepatic lipids, and body weight in a hamster model of hyperlipidemia, and it reduced body weight and improved glycemic control in a mouse model of diet-induced obesity.
Stephen L. Pinkosky et al. · Journal of Lipid Research · 2012

Why this rating

The evidence is derived from preclinical animal models (hamsters, mice, rats) and in vitro assays, not human clinical trials.

Source

AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism

Stephen L. Pinkosky et al. · Journal of Lipid Research · 2012

DOI 10.1194/jlr.m030528

mechanism_onlyCited 235×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →